Cargando…

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale

BACKGROUND: Rigorous data are sparse concerning the optimal route of administration and dosing strategy for iron therapy with or without concomitant erythropoiesis-stimulating agent (ESA) therapy for the management of iron deficiency anaemia in patients with non-dialysis dependent chronic kidney dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macdougall, Iain C., Bock, Andreas, Carrera, Fernando, Eckardt, Kai-Uwe, Gaillard, Carlo, Van Wyck, David, Roubert, Bernard, Cushway, Timothy, Roger, Simon D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	CLINICAL SCIENCE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967831/ https://www.ncbi.nlm.nih.gov/pubmed/24170814 http://dx.doi.org/10.1093/ndt/gft424

Ejemplares similares

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial
por: Gaillard, Carlo A., et al.
Publicado: (2016)

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017)

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017)

Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk
por: Ganz, Tomas, et al.
Publicado: (2020)

The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2017)

Correction to: The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2018)

Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
por: Roger, Simon D, et al.
Publicado: (2017)

Iron Deficiency in CKD Without Concomitant Anemia
por: Wish, Jay B., et al.
Publicado: (2021)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Rationale and design of a randomised trial of intravenous iron in patients with heart failure
por: Kalra, Paul R, et al.
Publicado: (2022)

A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD
por: Greenwood, Sharlene A., et al.
Publicado: (2023)

Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
por: Hedenus, Michael, et al.
Publicado: (2014)

Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study
por: AlSahow, Ali, et al.
Publicado: (2022)

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
por: Macdougall, Iain C
Publicado: (2017)

Intravenous Iron Repletion Does Not Significantly Decrease Platelet Counts in CKD Patients with Iron Deficiency Anemia
por: Dossabhoy, Neville R., et al.
Publicado: (2013)

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial
por: Kassianides, Xenophon, et al.
Publicado: (2022)

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
por: Riccio, Eleonora, et al.
Publicado: (2020)

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
por: Adkinson, N Franklin, et al.
Publicado: (2017)

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice
por: Richards, Toby, et al.
Publicado: (2021)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients
por: Liu, Huan, et al.
Publicado: (2022)

Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype
por: Armaly, Zaher, et al.
Publicado: (2015)

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
por: Macdougall, Iain C., et al.
Publicado: (2020)

Special issue: iron therapy in patients with chronic kidney disease
por: Macdougall, Iain C
Publicado: (2017)

Hypersensitivity to Intravenous Iron Preparations
por: Caimmi, Silvia, et al.
Publicado: (2022)

Ferrous iron content of intravenous iron formulations
por: Gupta, Ajay, et al.
Publicado: (2016)

Intravenous Iron Therapy with Saccharated Iron Oxide
por: Deshmukh, P. L.
Publicado: (1952)

Iron infusion and newer intravenous iron formulations
por: Aung, Tim, et al.
Publicado: (2021)

Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo
por: Faria, Bernardo, et al.
Publicado: (2019)

Chapter 2: Use of iron to treat anemia in CKD
Publicado: (2012)

Management of anaemia in CKD—the relative importance of erythropoietin and iron
por: Agarwal, Rajiv
Publicado: (2011)

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
por: Qunibi, Wajeh Y., et al.
Publicado: (2011)

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis
por: Petrie, Mark C, et al.
Publicado: (2021)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6i0raqbn504u9oa39mqmodaatf